¿Es el resmidir un tratamiento efectivo contra el COVID-19?

(Is remdesivir an effective treatment for covid-19)

Primeras 5 respuestas:

Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro,

Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses.

Remdesivir is one of the most promising drugs to treat COVID-19 based on the following facts:

Remdesivir is the most promising agent.

There is a need to identify effective, safe treatments for COVID-19 (coronavirus disease) rapidly, given the current, ongoing pandemic.

Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro,

... a high case fatality rate stresses the need for the availability of effective antiviral treatments. Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and showed efficacy against Severe Acute Respiratory Syndrome (SARS)-CoV in a mouse model. Here, we ...

Ref: Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection [Proc Natl Acad Sci U S A, 2020]

Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses.

... Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus Disease 19 (COVID-19). In this case report we summarize the use of ...

Ref: The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report [Case Rep Womens Health, 2020]

Remdesivir is one of the most promising drugs to treat COVID-19 based on the following facts:

... Remdesivir is one of the most promising drugs to treat COVID-19 based on the following facts: remdesivir has a broad-spectrum antiviral mechanism of action; it demonstrated in vitro activity against SARS-CoV-2 and in vivo efficacy in animal models against the similar coronavirus MERS-CoV; its safety profile ...

Ref: Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit [AAPS J, 2020]

Remdesivir is the most promising agent.

... potential drugs for treatment of COVID-19 are being investigated for safety and efficacy against SARS-CoV-2. Remdesivir is the most promising agent. In addition, favipiravir and combination therapy with hydroxychloroquine plus azithromycin appear to be acceptable alternatives ...

Ref: Treatment options for COVID-19: The reality and challenges [J Microbiol Immunol Infect, 2020-04-04]

There is a need to identify effective, safe treatments for COVID-19 (coronavirus disease) rapidly, given the current, ongoing pandemic.

... INTRODUCTION: There is a need to identify effective, safe treatments for COVID-19 (coronavirus disease) rapidly, given the current, ongoing pandemic. A systematic benefit-risk assessment was designed and conducted to examine the benefit-risk profile of remdesivir in COVID-19 patients compared with standard of care, placebo or other treatments. A key ...

Ref: Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment [Drug saf, 2020]

Remdesivir is the first antiviral treatment with proven efficacy against SARS-CoV-2 in an animal model of COVID-19.

... Remdesivir is the first antiviral treatment with proven efficacy against SARS-CoV-2 in an animal model of COVID-19. Remdesivir treatment in rhesus macaques infected with SARS-CoV-2 was highly effective in reducing clinical disease and damage to the lungs. The remdesivir dosing used in rhesus macaques is equivalent to ...

Ref: Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 [bioRxiv, 2020-04-22]

Remdesivir was thought to be one of the promising options for treating the patients of COVID-19

... to analyze the validity use of RDV because of the scarcity of evidence based reports. Remdesivir was thought to be one of the promising options for treating the patients of COVID-19 based on few laboratory experiments and reports from some compassionate use and case reports. The ...

Ref: Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences. [Mymensingh medical journal : MMJ, 2020-04-01]

remdesivir improves respiratory symptoms.

... antiviral effect on early replication of SARS‐CoV. Ribavirin reduces hemoglobin concentrations in respiratory patients, and remdesivir improves respiratory symptoms. Use of ribavirin in combination with LPV/r in patients with SARS‐CoV reduces acute respiratory distress ...

Ref: A global treatments for coronaviruses including COVID‐19 [J Cell Physiol, 2020-05-11]

Remdesivir is a potential drug for treatment of COVID-19.

... Remdesivir is a potential drug for treatment of COVID-19. It is a phosphoramidate prodrug of an adenosine C-nucleoside and a broad-spectrum antiviral agent synthesized and developed by Gilead Sciences in 2017 as a treatment for Ebola virus infection [28] ...

Ref: An Update on Current Therapeutic Drugs Treating COVID-19 [Curr Pharmacol Rep, 2020-05-11]

Effective therapeutics to treat COVID-19 are urgently needed.

... Effective therapeutics to treat COVID-19 are urgently needed. While many investigational, approved, and repurposed drugs have been suggested, preclinical data from animal models can guide the search for effective treatments by ruling out treatments without in vivo efficacy. ...

Ref: Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. [Nature, 2020-06-09]

Remdesivir, a nucleoside pro-drug that is thought to act by inhibiting viral RNA transcription,

... find an effective drug treatment because supportive care and oxygen supplementation is not always enough. Remdesivir, a nucleoside pro-drug that is thought to act by inhibiting viral RNA transcription, has shown in vitro antiviral activity against bat coronavirus and SARS-CoV-2, and has been safely ...

Ref: Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post_treatment hospitalisation status [Pharmacol Res, 2020-05-11]

a patient with COVID-19 was treated by intravenous remdesivir without apparent adverse reactions on the evening of the seventh day of hospitalization.

... reported in N Engl J Med, leading to widespread interest. 15 In this case report, a patient with COVID-19 was treated by intravenous remdesivir without apparent adverse reactions on the evening of the seventh day of hospitalization. The patient"s clinical symptoms improved on the eighth day after hospitalization (the 12th day after ...

Ref: Controversial treatments: An updated understanding of the coronavirus disease 2019 [J Med Virol, 2020-04-10]

Remdesivir is an anti-viral agent that has shown a significant inhibitory effect in vitro and in vivo studies against SARS-CoV-2

... Remdesivir is an anti-viral agent that has shown a significant inhibitory effect in vitro and in vivo studies against SARS-CoV-2 and appears to be ahead with other repurposed drug being tried for the treatment of COVID-19. Table 2 ...

Ref: Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies [Diabetes Metab Syndr, 2020-05-12]

Remdesivir is one of the most promising drugs for treatment of COVID-19,

... Remdesivir is one of the most promising drugs for treatment of COVID-19, but its efficacy may be limited by its poor physicochemical properties and poor tissue distribution/ penetration in the target organs (lung, spleen, lymph nodes, blood vessels, and others). Two approaches ...

Ref: Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit [AAPS J, 2020-05-26]

remdesivir was approved by Food and Drug Administration to treat COVID-19 through Emergency Use Authorization.

... new treatments, cures and supporting apparatuses. Recently, because of its positive results in clinical trials, remdesivir was approved by Food and Drug Administration to treat COVID-19 through Emergency Use Authorization. Here, we used molecular dynamics simulations and free energy perturbation methods to study the inhibition ...

Ref: Structural basis of potential binding mechanism of remdesivir to SARS-CoV-2 RNA dependent RNA polymerase [J. phys. chem. B, 2020]

Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo.

... BACKGROUND & AIMS: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe COVID-19. Newer randomized controlled studies that have ...

Ref: Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies [Diabetes Metab Syndr, 2020]

The remdesivir, an antiviral drug, is appeared as 'molecule of hope' for the treatment of this disease.

... now pandemic throughout the world. Scientist, doctors are searching for effective therapy of this diseases. The remdesivir, an antiviral drug, is appeared as "molecule of hope" for the treatment of this disease. USFDA gave emergency approval to this drug for the treatment of COVID-19. The molecular mechanism ...

Ref: Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More [Arch. med. res, 2020]

The clinical effectiveness and safety of these drugs for the treatment of COVID-19 remains unclear owing to the lack of large, high-quality RCTs.

... chloroquine, 29 for lopinavir/ritonavir, 14 for remdesivir, 16 for tocilizumab, and 4 for favipiravir. Conclusion: The clinical effectiveness and safety of these drugs for the treatment of COVID-19 remains unclear owing to the lack of large, high-quality RCTs. However, in the event of emerging infectious diseases, we need to repeatedly and systematically update ...

Ref: Current Evidence of the Pharmacological Treatments for Novel Coronavirus Disease 2019 (COVID-19) A Scoping Review [Arch. med. res, 2020-05-18]

clinical improvement was observed in 36 of 53 patients (68%).

... In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead ...

Ref: Compassionate Use of Remdesivir for Patients with Severe Covid-19 [N Engl J Med, 2020]

Remdesivir may or may not improve the clinical outcome of an individual subject with COVID-19 who participates in this trial.

... Remdesivir may or may not improve the clinical outcome of an individual subject with COVID-19 who participates in this trial. However, there is potential benefit to society from their participation in this study resulting from insights gained about the therapeutic agent under study as well as the natural history of ...

Ref: Remdesivir for the Treatment of Covid-19 — Preliminary Report [N Engl J Med, 2020-05-22]

Remdesivir is a nucleotide prodrug that is currently undergoing extensive clinical trials for the treatment of COVID-19.

... Remdesivir is a nucleotide prodrug that is currently undergoing extensive clinical trials for the treatment of COVID-19. The prodrug is metabolized to its active triphosphate form and interferes with the action of RNA-dependent RNA polymerase of SARS-COV-2. Herein, we report the antiviral activity of remdesivir against human ...

Ref: Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E) [Molecules (Basel), 2020]

The current COVID-19 pandemic caused by SARS-CoV-2 has prompted investigators worldwide to search for an effective anti-viral treatment.

... The current COVID-19 pandemic caused by SARS-CoV-2 has prompted investigators worldwide to search for an effective anti-viral treatment. A number of anti-viral drugs such as ribavirin, remdesivir, lopinavir/ritonavir, antibiotics such as azithromycin and doxycycline, and anti-parasite such as ivermectin have been recommended for COVID-19 treatment. In addition, sufficient ...

Ref: Can Zn Be a Critical Element in COVID-19 Treatment? [Biol. trace elem. res, 2020]

Remdesivir has emerged as a promising treatment for SARS-Co-V-2 infection

... interventions and disseminate information. This has led to confusing and conflicting information on drug efficacy. Remdesivir has emerged as a promising treatment for SARS-Co-V-2 infection yet published clinical pharmacology and drug interaction studies are limited. Additional studies of the disposition ...

Ref: What do we know about remdesivir drug interactions? [Biol. trace elem. res, 2020]

One such proposed treatment is remdesivir, which is an investigational antiviral medicine with proven activity against RNA viruses [6, 7] .

... Currently, there is a need to identify effective, safe treatments for COVID-19 as quickly as possible, due to the ongoing pandemic. One such proposed treatment is remdesivir, which is an investigational antiviral medicine with proven activity against RNA viruses [6, 7] . Remdesivir was ...

Ref: Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment [Drug Saf, 2020-05-28]

The remdesivir, an antiviral drug, is appeared as ‘molecule of hope’ for the treatment of this disease.

... now pandemic throughout the world. Scientist, doctors are searching for effective therapy of this diseases. The remdesivir, an antiviral drug, is appeared as ‘molecule of hope’ for the treatment of this disease. USFDA approve this drug for the treatment of COVID-19. The molecular mechanism is unknown. In ...

Ref: Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More [Arch Med Res, 2020-05-12]

No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19).

... BACKGROUND: No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East ...

Ref: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [Lancet, 2020]

GS-5734 (Remdesivir) is a safe and effective drug for the treatment of COVID-19.

... drugs are capable of inhibiting coronavirus infections, GS-5734 should be considered a broad-spectrum, first-line drug and may inhibit coronavirus infections and COVID-19. More clinical trials are needed to prove that GS-5734 (Remdesivir) is a safe and effective drug for the treatment of COVID-19. ...

Ref: Vytr hypothesis for the prophylactic and therapeutic efficacy of GS-5734 treatment in humans with COVID-19 [Int. J. Res. Pharm. Sci., 2020]

Remdesivir has shown in vitro activity against coronaviruses and is a possible antiviral treatment for SARS-CoV-2 infection.

... is causing an increasing number of deaths worldwide because no effective treatment is currently available. Remdesivir has shown in vitro activity against coronaviruses and is a possible antiviral treatment for SARS-CoV-2 infection. This prospective (compassionate), open-label study of remdesivir, which was conducted at Luigi Sacco Hospital, Milan, ...

Ref: Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status [Pharmacol Res, 2020]

remdesivir has demonstrated potent antiviral activity against diverse human and zoonotic ß-coronaviruses, including SARS-CoV-2.

... delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis. In pre-clinical models, remdesivir has demonstrated potent antiviral activity against diverse human and zoonotic ß-coronaviruses, including SARS-CoV-2. In this article we critically review available data on remdesivir with an emphasis on biochemistry, ...

Ref: Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19 [Pharmacotherapy, 2020]

Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection.

... and 141 of the 522 patients in the placebo group who underwent randomization (27.0%). CONCLUSIONS: Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 ClinicalTrials.gov number, ...

Ref: Remdesivir for the Treatment of Covid-19 - Preliminary Report [N. Engl. j. med, 2020]

remdesivir has been tried for a compassionate use in severe COVID-19.

... in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe COVID-19. Newer randomized controlled studies that have recently become available, showed a mixed result. We aimed ...

Ref: Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies [Diabetes Metab Syndr, 2020]

Remdesivir holds promise for treating COVID-19 based on in vitro activity against SARS-CoV-2,

... it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak. Remdesivir holds promise for treating COVID-19 based on in vitro activity against SARS-CoV-2, uncontrolled clinical reports, and limited data from randomized trials. Overall, current data are insufficient to ...

Ref: The journey of remdesivir: from Ebola to COVID-19 [Drugs Context, 2020-05-22]

On average, COVID-19 51 symptoms lasted 12 days before remdesivir therapy was initiated.

... 9-50 day therapy and 3 patients received less than 5 days of remdesivir (7) . On average, COVID-19 51 symptoms lasted 12 days before remdesivir therapy was initiated. In the median follow-up period of 52 18 days, 36 of the 53 patients (68%) ...

Ref: Remdesivir investigational trials in COVID-19: a critical reappraisal [New Microbes New Infect, 2020-06-07]

Remdesivir is an investigational drug having broad spectrum antiviral activity with its target RNA dependent RNA polymerase.

... available evidence and ongoing clinical trials of remdesivir as a potential therapeutic option for COVID-19. Remdesivir is an investigational drug having broad spectrum antiviral activity with its target RNA dependent RNA polymerase. It has not yet been officially approved for Ebola and Coronaviruses. Several studies showed that ...

Ref: Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19? [Front Pharmacol, 2020-05-26]

An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed.

... An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. ...

Ref: Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro [Antiviral Res, 2020]

Its beneficial use for COVID-19 patients has been controversial.

... been used to treat malaria and chronic inflammatory diseases such as "lupus" and "rheumatoid arthritis". Its beneficial use for COVID-19 patients has been controversial. The first open-label, RCT was published on 14th April 2020, which demonstrated that there was ...

Ref: Covering coronavirus—emerging tools for the fight against the common enemy [Oxf Med Case Reports, 2020-06-13]

Remdesivir has emerged as a promising treatment for SARS‐Co‐V‐2 infection

... interventions and disseminate information. This has led to confusing and conflicting information on drug efficacy. Remdesivir has emerged as a promising treatment for SARS‐Co‐V‐2 infection yet published clinical pharmacology and drug interaction studies are limited. Additional studies of the disposition ...

Ref: What do we know about remdesivir drug interactions? [Clin Transl Sci, 2020-05-13]

Remdesivir is effective against a broad spectrum of human and pre-epidemic zoonotic CoVs

... [30] . Biochemical studies indicate that remdesivir acts as a non-obligate chain terminator [31] . Remdesivir is effective against a broad spectrum of human and pre-epidemic zoonotic CoVs and potently inhibits replication of SARS-CoV and MERS-CoV in primary human airway epithelial cultures (Table ...

Ref: Nucleoside analogues for the treatment of coronavirus infections [Curr Opin Virol, 2019-05-21]

The report from Beigel et al. shows that remdesivir provides moderate clinical benefit in the treatment of patients with Covid-19.

... The report from Beigel et al. shows that remdesivir provides moderate clinical benefit in the treatment of patients with Covid-19. The findings presented are preliminary and are to be followed by a more complete gathering of data and a full statistical study of the entire study population. The initial findings ...

Ref: Remdesivir — An Important First Step [N Engl J Med, 2020-05-27]

The effective dose for treatment of COVID-19 is unknown.

... times/ day or 1250 mg by mouth twice/day. The halflife of nelfinavir is 3.5-5 hours. The effective dose for treatment of COVID-19 is unknown. Nelfinavir dosage adjustments do not need to be made with renal impairment because less than ...

Ref: Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 [Pharmacotherapy, 2020-05-06]

No specific therapies/vaccines are yet available for the treatment of COVID-19.

... Since December 2019 SARS-Cov-2 was found responsible for the disease COVID-19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVID-19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including ...

Ref: Current pharmacological treatments for COVID-19: What's next? [Br. j. pharmacol, 2020]

Remdesivir was used to treat the first case of COVID-19 infection in the United States:

... chain termination was delayed, which explained the high potency of remdesivir against RNA [52] . Remdesivir was used to treat the first case of COVID-19 infection in the United States: the patient"s clinical condition improved after only one day of remdesivir treatment [53] . A ...

Ref: The epidemiology, diagnosis and treatment of COVID-19 [Int J Antimicrob Agents, 2020-03-28]

remdesivir provides moderate clinical benefit in the treatment of patients with Covid-19.

Ref: Remdesivir — An Important First Step [N Engl J Med, 2020-05-27]

Remdesivir is considered the most promising antiviral agent; it works by inhibiting the activity of RNA-dependent RNA polymerase (RdRp).

... are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Remdesivir is considered the most promising antiviral agent; it works by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). A large-scale study investigating the clinical efficacy of remdesivir (200 mg on day 1, followed ...

Ref: Treatment options for COVID-19: The reality and challenges [J Microbiol Immunol Infect, 2020]

Remdesivir had been proposed as a promising option for treating coronavirus disease 2019 (COVID-19).

... The outbreak of SARS-CoV-2 rapidly spread across China and worldwide. Remdesivir had been proposed as a promising option for treating coronavirus disease 2019 (COVID-19). We provided a rapid review to critically assess the potential anti-coronavirus effect of remdesivir on COVID-19 and other coronaviruses based ...

Ref: Rapid review for the anti-coronavirus effect of remdesivir [Drug Discov Ther, 2020]

Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity1,2,

... can guide the search for effective treatments by ruling out treatments without in vivo efficacy. Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity1,2, that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from ...

Ref: Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. [Nature, 2020-06-09]

Several Phase III trials are underway to determine the efficacy of remdesivir in the treatment of COVID-19 (2) .

... Several Phase III trials are underway to determine the efficacy of remdesivir in the treatment of COVID-19 (2) . As of now, remdesivir may be considered in patients with severe disease and respiratory failure (8) . It cannot be used in conjunction with hydroxychloroquine due to an increased risk ...

Ref: Pharmacotherapy in COVID-19; A narrative review for emergency providers [Am J Emerg Med, 2020-04-15]

Remdesivir, a nucleotide-analogue antiviral drug developed for Ebola, is determined to prevent and stop infections with COVID-19,

... no approved vaccines or drugs to make the disease less deadly, while efforts are underway. Remdesivir, a nucleotide-analogue antiviral drug developed for Ebola, is determined to prevent and stop infections with COVID-19, while results are yet controversial. Here, we aim to conduct a systematic review and meta-analysis ...

Ref: Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials [BMJ Open, 2020]

The use of these off-label medications may be beneficial in the treatment of the COVID-19.

... is also exciting to uncover that Flavin Adenine Dinucleotide (FAD) Adeflavin, B2 deficiency medicine, and Coenzyme A, a coenzyme, may also be potentially used for the treatment of SARS-CoV-2 infections. The use of these off-label medications may be beneficial in the treatment of the COVID-19. ...

Ref: A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease [Travel Med Infect Dis, 2020]

Late initiation of remdesivir may be effective in treating SARS-CoV-2,

... Late initiation of remdesivir may be effective in treating SARS-CoV-2, unlike antivirals such as oseltamivir and acyclovir, which are most effective when started as soon as possible following symptom onset. This case highlights the urgent need for action by regulatory ...

Ref: Delayed Initiation of Remdesivir in a COVID‐19‐Positive Patient [Pharmacotherapy, 2020-05-20]

Remdesivir has received significant attention for its potential application in the treatment of COVID-19, caused by SARS-CoV-2.

... BACKGROUND: Remdesivir has received significant attention for its potential application in the treatment of COVID-19, caused by SARS-CoV-2. Remdesivir has already been tested for Ebola virus disease treatment and found to have activity against SARS and MERS coronaviruses. The remdesivir core contains GS-441524, which interferes with RNA-dependent ...

Ref: Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease [J. antimicrob. chemother, 2020]

Finding efficacious and safe treatments for COVID-19 emerges as a crucial need in order to control the spread of the pandemic.

... Finding efficacious and safe treatments for COVID-19 emerges as a crucial need in order to control the spread of the pandemic. Whereas plasma therapy attracts much interest, the European project Discovery focuses on the potentialities of small molecules like remdesivir, the combination of lopinavir/ritonavir, hydroxychloroquine, and chloroquine. Results recently published on ...

Ref: COVID-19: An Update about the Discovery Clinical Trial [Pharmaceuticals (Basel), 2020-05-14]

Remdesivir might be crucial for ensuring an efficient treatment, decrease mortality and allow early discharge in relation to Covid-19.

Remdesivir might be crucial for ensuring an efficient treatment, decrease mortality and allow early discharge in relation to Covid-19. Ongoing randomized, placebo-controlled trials are critical in delineating its efficacy.

Ref: Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary [J Biomol Struct Dyn, 2020-05-20]

Remdesivir, used as a positive control, showed potent antiviral activity (EC50 = 0.38 μM).

... SARS-CoV-2 was assessed. DRV showed no activity against SARS-CoV-2 at clinically relevant concentrations (EC50 >100 μM). Remdesivir, used as a positive control, showed potent antiviral activity (EC50 = 0.38 μM). Overall, the data do not support the use of DRV for treatment of COVID-19. ...

Ref: Lack of Antiviral Activity of Darunavir against SARS-CoV-2 [J Biomol Struct Dyn, 2020-04-08]

The first medication experience of the recovered patients in the US has led remdesivir to be the 'specific drug'.

... cannot be applied immediately to patients, "conventional drug in new use" becomes a feasible solution. The first medication experience of the recovered patients in the US has led remdesivir to be the "specific drug". China has also taken immediate action to put remdesivir into clinical trials with the purpose ...

Ref: Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence [Travel Med Infect Dis, 2020]

Based on the current evidence, 5-day course of Remdesivir therapy in COVID-19 patients is probably efficacious and safe.

... Based on the current evidence, 5-day course of Remdesivir therapy in COVID-19 patients is probably efficacious and safe. Remdesivir efficacy differs in different disease severity subgroups and hospitalized patients without invasive mechanical ventilation benefit the most from Remdesivir. Treatment can be extended to 10 days if satisfactory improvement ...

Ref: Remdesivir Efficacy in Coronavirus Disease 2019 (COVID-19): A Systematic Review [Travel Med Infect Dis, 2020-06-16]

Another interesting strategy is to use convalescent plasma (CP) as treatment,

... Another interesting strategy is to use convalescent plasma (CP) as treatment, but it 238 should be noted that CP should be collected within two weeks after recovery to ensure 239 a high neutralization antibody titer [50] . It was reported that ...

Ref: Current development of COVID-19 diagnostics, vaccines and therapeutics [Microbes Infect, 2020-05-06]

Remdesivir has shown a mixed result in patients with COVID-19 with an acceptable side effect.

... multi-country trial has shown a significant faster time to recovery but without any difference in mortality. CONCLUSIONS: Remdesivir has shown a mixed result in patients with COVID-19 with an acceptable side effect. However, jury is still out while awaiting the results from the forthcoming trials. ...

Ref: Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies [Diabetes Metab Syndr, 2020-05-12]

Currently, there is a need to identify effective, safe treatments for COVID-19 as quickly as possible, due to the ongoing pandemic.

Ref: Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment [Diabetes Metab Syndr, 2020-05-12]

Emerging clinical evidence and available in vitro data suggest remdesivir is a promising agent for the treatment of COVID-19.

... Emerging clinical evidence and available in vitro data suggest remdesivir is a promising agent for the treatment of COVID-19. Institutions should explore clinical trial enrollment or compassionate use remdesivir for moderate-to-severe patients. Additional clinical data are eagerly anticipated and should help further define the role of this agent in ...

Ref: Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options [Open Forum Infect Dis, 2020-03-23]

There is a need to identify effective, safe treatments for COVID-19 (coronavirus disease) rapidly,

Ref: Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment [Drug saf, 2020]

Remdesivir is undergoing a large number of clinical trials in several hospitals, and the final efficacy of the drug is uncertain.

... Chloroquine was proved to be effective in the treatment of patients with COVID-19 [47] . Remdesivir is undergoing a large number of clinical trials in several hospitals, and the final efficacy of the drug is uncertain. Arbidol, a small indole derivative molecule, was found to block viral fusion against influenza A ...

Ref: A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence [Int J Antimicrob Agents, 2020-03-19]

Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures,

... remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in nonhuman animal models. In addition, a combination of the human ...

Ref: Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus [Antimicrob Agents Chemother, 2020-04-21]

remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus,

... treat human immunodeficiency virus (HIV) infection) in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxy- chloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) ...

Ref: SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus [Curr. med. chem, 2020]

Remdesivir is one of the most promising drugs to treat COVID-19

Ref: Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit [AAPS J, 2020]

Remdesivir is an investigational nucleoside analog that works as an RNA-chain terminator by inhibiting RNA-dependent viral RNA polymerase.

... Remdesivir is an investigational nucleoside analog that works as an RNA-chain terminator by inhibiting RNA-dependent viral RNA polymerase. It is a monophosphoramidate prodrug of adenosine C-nucleoside 59 , and its structure is similar to tenofovir alafenamide, which is active against HIV and hepatitis B virus. 60 Europe, including ...

Ref: Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof) [Mayo Clin Proc, 2020-04-30]

Remdesivir has garnered considerable interest as a treatment for COVID-19 since May 2020 when it was granted EUA status.

... Remdesivir has garnered considerable interest as a treatment for COVID-19 since May 2020 when it was granted EUA status. 13 A recent randomized placebo controlled trial by Wang et al. did not establish significant benefit of remdesivir and was terminated early. 24 Serious adverse events occurred in 18% and ...

Ref: Multicenter point-prevalence evaluation of the utilization and safety of drug therapies for COVID-19 [Mayo Clin Proc, 2020-06-06]

proposing and validating effective treatments represents a major challenge.

... In the current COVID-19 pandemic context, proposing and validating effective treatments represents a major challenge. However, the lack of biologically relevant pre-clinical experimental models of SARS-CoV-2 infection as a complement of classic cell lines represents a major barrier for ...

Ref: Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia [bioRxiv, 2020-04-02]

Remdesivir will be used primarily in severe disease and is administered intravenously, so not a practical outpatient treatment.

... in mild to moderate disease. They also had no control group for HCQ plus AZT. Remdesivir will be used primarily in severe disease and is administered intravenously, so not a practical outpatient treatment. Favipiravir is an oral tablet, like remdesivir an inhibitor of RNA polymerase, and is in ...

Ref: A SYSTEMATIC ANALYSIS OF THE TIME COURSE TO DEVELOP TREATMENTS FOR COVID-19 [bioRxiv, 2020-06-02]

remdesivir or EIDD-2801, as a treatment for patients positive for SARS-CoV-2.

... the combination of copper, N-acetylcysteine (NAC), colchicine and nitric oxide (NO) with candidate antiviral agents, remdesivir or EIDD-2801, as a treatment for patients positive for SARS-CoV-2. CONCLUSION The authors propose to study the effects of the combination of copper, NAC, colchicine, ...

Ref: COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. [In vivo, 2020-06-01]

Remdesivir is an intravenous investigational drug with strong antiviral activity.

... Remdesivir is an intravenous investigational drug with strong antiviral activity. It has activity against COVID-19 and other related beta-coronaviruses. This drug is not effective in Ebola, but in a laboratory, study remdesivir can prevent human cells from being infected with ...

Ref: COVID-19 and therapeutic drugs repurposing in hand: the need for collaborative efforts [Le Pharmacien Hospitalier et Clinicien, 2020-06-13]

Remdesivir is a promising drug candidate to treat COVID-19 infection [20] [21] [22] .

... Remdesivir is a promising drug candidate to treat COVID-19 infection [20] [21] [22] . It has been shown to be effective as compassionate-use basis to patients hospitalised with COVID-19 22 , including those suffering from pneumonia 20 . Subsequently, clinical trials on using remdesivir ...

Ref: Role of 1’-Ribose Cyano Substitution for Remdesivir to Effectively Inhibit both Nucleotide Addition and Proofreading in SARS-CoV-2 Viral RNA Replication [bioRxiv, 2020-04-27]

Remdesivir has potent in vitro activity against SARS-CoV-2,

... virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested ...

Ref: Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review [JAMA, 2020]

Remdesivir has received significant attention for its potential application in the treatment of COVID-19,

For the treatment of ordinary and severe COVID-19 pneumonia,

... terminal phosphorylation of ACE2, or hydroxychloroquine which is metabolized in vivo to chloroquine [44] . For the treatment of ordinary and severe COVID-19 pneumonia, and to lower the mortality rate of COVID-19 disease, the antiviral drugs remdesivir, favipiravir, umifenovir, ...

Ref: Candidate drugs against SARS-CoV-2 and COVID-19 [Pharmacol Res, 2020-04-29]

remdesivir, which exhibits promising in vitro antiviral activity and preliminary clinical experiences in the treatment of COVID-19.

... [m5G; March 16, 2020; 7:11 ] be gained from its more well-known family member, SARS-CoV [11] . Here we review the literature on an existing but not approved antiviral agent, remdesivir, which exhibits promising in vitro antiviral activity and preliminary clinical experiences in the treatment of COVID-19. ...

Ref: Arguments in favour of remdesivir for treating SARS-CoV-2 infections [Int J Antimicrob Agents, 2020-03-06]

Currently, remdesivir appears to be the most promising drug for the treatment of pneumonia caused by COVID-19 pneumonia.

... Currently, remdesivir appears to be the most promising drug for the treatment of pneumonia caused by COVID-19 pneumonia. Many other agents or strategies are being tested for the treatment of patients with COVID-19. However, double-blind, randomized controlled trials are required to investigate their safety and efficacy. ...

Ref: Emerging Therapeutic Strategies for COVID-19 patients [Discoveries (Craiova), 2020-03-12]

Remdesivir (GS-5734), a nucleoside analogue, has inhibitory effects on animal and human highly pathogenic coronaviruses,

... failure, and even death. There are no antivirals of proven clinical efficacy in coronavirus infections. Remdesivir (GS-5734), a nucleoside analogue, has inhibitory effects on animal and human highly pathogenic coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and in vivo experiments. It is also inhibitory ...

Ref: Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial [Trials, 2020]

Drugs targeting RNA respiratory viruses has resulted in few effective therapies, highlighting challenges for antivirals to treat COVID-19.

... Drugs targeting RNA respiratory viruses has resulted in few effective therapies, highlighting challenges for antivirals to treat COVID-19. Several antivirals are being investigated for symptomatic COVID-19 but no definitive data support their clinical use. Remdesivir, with good in vitro activity against SARS-CoV2, appeared to result in favorable outcomes ...

Ref: Antivirals for COVID-19. [Cleveland Clinic journal of medicine, 2020-05-14]

the clinical and antiviral efficacy of remdesivir in COVID-19 remains to be established.

... Case studies have reported benefit in severely ill patients with COVID-19. 5, 21, 22 However, the clinical and antiviral efficacy of remdesivir in COVID-19 remains to be established. Here, we report the results of a placebocontrolled randomised trial of remdesivir in patients with ...

Ref: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [Lancet, 2020-04-29]

We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19,

... analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. METHODS: We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who ...

Ref: Compassionate Use of Remdesivir for Patients with Severe Covid-19 [N Engl J Med, 2020-04-10]

Several clinical trials are investigating the efficacy and tolerability of chloroquine in the prevention and treatment of COVID-19 (Table 1) .

... of the virus into the cells. In cell cultures, the replication of SARS-CoV-2 was inhibited at a chloroquine concentration (EC50 = concentration with half-maximal effect) of 1.13 μM (6) . Several clinical trials are investigating the efficacy and tolerability of chloroquine in the prevention and treatment of COVID-19 (Table 1) . ...

Ref: Medication for COVID-19—an Overview of Approaches Currently Under Study [Dtsch Arztebl Int, 2020-03-27]

our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir.

... level (7%), and constipation (7%). CONCLUSIONS In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. (Funded by Gilead ...

Ref: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. [The New England journal of medicine, 2020-05-27]

We are moderately confident remdesivir in patients hospitalized with COVID-19 leads to faster clinical improvement,

... We are moderately confident remdesivir in patients hospitalized with COVID-19 leads to faster clinical improvement, with an important and significant decrease in time to clinical improvement using remdesivir of 3.95 fewer days, ranging from 4.05 fewer to 3.86 fewer days. We are highly confident in ...

Ref: Remdesivir use in patients with coronavirus COVID-19 disease: a systematic review and meta-analysis [The New England journal of medicine, 2020-05-26]

COVID-19 poses a great threat to global health and safety.

... COVID-19 poses a great threat to global health and safety. It is an urgent task for us to control the spread of the epidemic and reduce the mortality rate as soon as possible. But so far, the specific mechanism of ...

Ref: A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19) [Pharmacol Res, 2020-05-20]

The use of other potential drugs reported in different studies may be considered if treatment with first-line drugs is ineffective.

... lopinavir/ritonavir, and one of the investigational agents (remdesivir) are recommended in critically ill older patients. The use of other potential drugs reported in different studies may be considered if treatment with first-line drugs is ineffective. There are currently no complete data available from large randomized clinical trials (RCTs) to provide ...

Ref: Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action [Adv Ther, 2020-04-29]

In the current COVID-19 pandemic context, proposing and validating effective treatments represents a major challenge.

Ref: Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia [bioRxiv, 2020-04-02]

Currently, none of the drugs on the market is really effective against COVID-19.

... Currently, none of the drugs on the market is really effective against COVID-19. The new antiviral drugs should ensure better pharmacokinetic properties, greater potency and/or a lower toxicity profile than currently available therapies. The combined use of multiple antiviral drugs is the right ...

Ref: Covid-19 and drug therapy, what we learned [Int J Clin Pharm, 2020-05-07]

In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients.

... list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and ...

Ref: An Update on Current Therapeutic Drugs Treating COVID-19 [Curr Pharmacol Rep, 2020]

Remdesivir and convalescent plasma may be considered in critical patients with respiratory failure;

... is unavailable, in patients with moderate disease, although these recommendations are based on limited evidence. Remdesivir and convalescent plasma may be considered in critical patients with respiratory failure; however, access to these therapies may be limited. Interleukin-6 (IL-6) antagonists may be used in ...

Ref: Pharmacotherapy in COVID-19; A narrative review for emergency providers [Am. j. emerg. med, 2020]

Treatment with intravenous remdesivir showed significant improvement for the first COVID-19 case in US [24]

... suggesting its working concentration is likely to be achieved in nonhuman primate models [8] . Treatment with intravenous remdesivir showed significant improvement for the first COVID-19 case in US [24] and then a trial has been initiated quickly to assess the efficacy and safety of ...

Ref: Antiviral treatment of COVID-19 [Turk J Med Sci, 2020-04-21]

Remdesivir has been shown to inhibit COVID-19 potently in cell cultures.

... epidemic, the monoclonal antibodies mAb114 and REGN-EB3 were superior to remdesivir in reducing mortality. 5 Remdesivir has been shown to inhibit COVID-19 potently in cell cultures. 43 In the compassionate use of remdesivir on 61 patients, clinical improvement was observed in ...

Ref: Potential specific therapies in COVID-19 [Ther Adv Respir Dis, 2020-05-21]

exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients.

... locality. A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50 % maximal effective concentrations (EC50) ...

Ref: Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system [Pharmacol Res, 2020]

damage seen in COVID-19 is due to a 'cytokine storm',

... g e : w w w . e u r o p e a n u r o l o g y . damage seen in COVID-19 is due to a "cytokine storm", 100 release of proinflammatory cytokines including IL-6 ...

Ref: Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials [Eur Urol Focus, 2020-06-05]

Effective treatments for COVID-19 are urgently needed.

... Effective treatments for COVID-19 are urgently needed. While a large number of investigational as well as approved and repurposed drugs have been suggested to have utility for treatment of COVID-19, preclinical data from animal models can guide ...

Ref: Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 [bioRxiv, 2020-04-22]

We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy,

... We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to ...

Ref: Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report [Int. j. infect. dis, 2020]

It is also inhibitory against the COVID-19 virus in vitro.

... human highly pathogenic coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and in vivo experiments. It is also inhibitory against the COVID-19 virus in vitro. The aim of this study is to assess the efficacy and safety of remdesivir in ...

For COVID-19 no specific medication is available, remdesivir is expected to be a 'specific drug'.

... improved significantly within 24 h, bringing hope for the treatment of patients with severe COVID-19. For COVID-19 no specific medication is available, remdesivir is expected to be a "specific drug". However, for the acute infectious diseases, reducing the number of viral copies in the body ...

Ref: Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence [Travel Med Infect Dis, 2020-04-02]

We aimed to demonstrate the effect of anti-COVID-19 agent remdesivir on renal fibrosis.

... Aim Kidney impairment is observed in patients with COVID-19. We aimed to demonstrate the effect of anti-COVID-19 agent remdesivir on renal fibrosis. Methods Remdesivir and its active nucleoside metabolite GS-441524 were used to treat TGF-β stimulated renal fibroblasts (NRK-49F) and human renal epithelial ...

Ref: Remdesivir inhibits renal fibrosis in obstructed kidneys [bioRxiv, 2020-04-03]

COVID-19 disease appears to be a spectrum of clinical presentations ranging from asymptomatic to severe respiratory failure.

... COVID-19 disease appears to be a spectrum of clinical presentations ranging from asymptomatic to severe respiratory failure. Common symptomology at the onset of illness are fever, cough, and general myalgia, with less common symptoms including sputum production, headache, and diarrhea. 9−11 An initial case analysis from China ...

Ref: Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 [ACS Cent Sci, 2020-05-04]